[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
July 9, 2008

Incorrect Numbers in Table in: Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial

JAMA. 2008;300(2):170. doi:10.1001/jama.300.2.170-a

Incorrect Numbers in Table: In the Original Contribution entitled “Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial” published in the September 12, 2007, issue of JAMA (2007;298[10]:1163-1170), a row of data was erroneously calculated in Table 4. For the secondary outcome of thrombosis in hemodialysis patients (final row of the table), the denominator should have been (n = 1208), which reflects only those patients who received hemodialysis in the study (618 in the vitamin group and 590 in the placebo group). The corresponding hazard ratio should have been 1.00 (95% confidence interval, 0.80-1.24; P = .96). The effect of treatment remained nonsignificant.

×